Vaccine advisers to the United States Food and Drug Administration (FDA) recommended the Moderna COVID-19 booster shot for emergency use authorization on Oct. 14.
The Vaccine and Related Biological Products Advisory Committee voted unanimously in favor of authorizing the booster shots, sending the final decision of authorization to the FDA.
The booster shot would be authorized for people aged 65 and older, people aged 18 to 64 who are at high risk of severe COVID-19, and people aged 18 to 64 whose exposure to the virus due to their jobs put them at risk of COVID-19 complications or severe illness.
Moderna Chief Executive Stéphane Bancel thanked the committee in a statement for the recommendation of the vaccine that “shows robust antibody responses against the original virus, but also against the Delta variant.”
“We remain committed to staying ahead of the virus and following the evolving epidemiology of SARS-CoV-2. We look forward to making our booster available to people in the U.S. to help protect themselves against this ongoing public health emergency,” Bancel further said.
Moderna estimates that the unanimous positive vote and subsequent final authorization could result in up to one billion additional doses being available for distribution in 2022.
The Moderna booster shot should be administered at least six months after the primary two-dose series.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.